MARKET

XAIR

XAIR

Beyond Air Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.77
-0.30
-4.24%
After Hours: 6.89 +0.12 +1.77% 16:12 01/21 EST
OPEN
7.01
PREV CLOSE
7.07
HIGH
7.20
LOW
6.44
VOLUME
326.92K
TURNOVER
--
52 WEEK HIGH
16.41
52 WEEK LOW
4.620
MARKET CAP
180.35M
P/E (TTM)
-5.4308
1D
5D
1M
3M
1Y
5Y
Beyond Air Inc (XAIR) CEO and Chairman of the Board Steven A. Lisi Bought $341,200 of Shares
CEO and Chairman of the Board of Beyond Air Inc (30-Year Financial, Insider Trades) Steven A. Lisi (insider trades) bought 40,000 shares of XAIR on 12/10/2021 at an average price of $8.53 a share.
GuruFocus.com · 12/14/2021 14:15
Beyond Air CEO buys $341K in common stock
In a regulatory filing, Beyond Air (NASDAQ:XAIR) disclosed that its CEO Steven Lisi bought 40K shares of common stock at $8.53 for a total outlay of $341K on December 10th, boosting his
Seekingalpha · 12/14/2021 11:11
Implied Volatility Surging for Beyond Air (XAIR) Stock Options
Investors need to pay close attention to Beyond Air (XAIR) stock based on the movements in the options market lately.
Zacks · 12/10/2021 14:14
Beyond Air Shares Fall As US Launch Of LungFit PH Not Expected In 2021
Benzinga · 12/09/2021 18:28
38 Stocks Moving In Thursday's Mid-Day Session
Gainers
Benzinga · 12/09/2021 17:21
Inspira Technologies, Ensysce Biosciences leads healthcare gainers; Reata Pharmaceuticals, Beyond Air among major losers
Gainers: Inspira Technologies (NASDAQ:IINN) +103%, Ensysce Biosciences (NASDAQ:ENSC) +53%, Jasper Therapeutics (NASDAQ:JSPR) +24%, Ambrx Biopharma (NYSE:AMAM) +17%, iSpecimen (NASDAQ:ISPC) +15%. Losers: Reata Pharmaceuticals (NASDAQ:RETA) -43%, Beyond Air ...
Seekingalpha · 12/09/2021 16:12
Beyond Air says U.S. launch of LungFit system unlikely before year-end
Beyond Air (XAIR -22.9%) shares have approached the lowest level since mid-August after the company cited its ongoing discussions with the FDA to indicate that its U.S. commercial launch of
Seekingalpha · 12/09/2021 15:52
BRIEF-Beyond Air Provides Regulatory Update For Lungfit PH
reuters.com · 12/09/2021 13:55
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of XAIR. Analyze the recent business situations of Beyond Air Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

40.00%Strong Buy
60.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average XAIR stock price target is 15.40 with a high estimate of 17.00 and a low estimate of 13.00.
High17.00
Average15.40
Low13.00
Current 6.77
EPS
Actual
Estimate
-0.29-0.22-0.14-0.07
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Institutional Holdings
Institutions: 62
Institutional Holdings: 4.72M
% Owned: 17.71%
Shares Outstanding: 26.64M
TypeInstitutionsShares
Increased
22
675.96K
New
9
433.96K
Decreased
8
125.64K
Sold Out
16
772.65K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-0.93%
Healthcare Equipment & Supplies
-1.50%
Key Executives
Chairman/Chief Executive Officer/Director
Steven Lisi
President/Chief Operating Officer/Director
Amir Avniel
Chief Financial Officer
Douglas Larson
Other
Andrew Colin
Other
Duncan Fatkin
Other
Peter Senior
Independent Director
Ron Bentsur
Independent Director
Robert Carey
Independent Director
William Forbes
Independent Director
Yoori Lee
Independent Director
Erick Lucera
No Data
About XAIR
Beyond Air, Inc. is a clinical-stage medical device and biopharmaceutical company. The Company is engaged in developing a nitric oxide (NO) generator and delivery system through its LungFit platmorfm that is capable of generating NO from ambient air. Its pipeline includes LungFit PH designed to deliver a dosage of NO to the lungs for the treatment of Persistent Pulmonary Hypertension of the Newborn (PPHN), LungFit PRO for the treatment of viral lung infections for adults, which is commonly caused by rhinovirus, respiratory syncytial virus (RSV) and influenza virus and LungFit GO for the treatment of rare and serious pulmonary disease associated with increased morbidity and mortality called Nontuberculous mycobacteria (NTM) lung infection.

Webull offers kinds of Beyond Air Inc stock information, including NASDAQ:XAIR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XAIR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading XAIR stock methods without spending real money on the virtual paper trading platform.